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In vitro biocompatibility performance of Physioneal. Peri-
toneal dialysis (PD) has been a successful and effective form of
chronic renal replacement therapy since its introduction over
20 years ago. Despite its overall success, there is a growing
body of evidence that suggests shortcomings in the preser-
vation of membrane integrity. This has led to the develop-
ment of several second-generation PD solutions that demon-
strate improved biocompatibility. Physioneal, a neutral pH,
bicarbonate/lactate-buffered solution, was one of the first of
these new PD solutions to become commercially available.
This review will focus on one of the first preclinical stages in
the development of Physioneal: studies on in vitro biocom-
patibility testing. Studies in leukocyte, mesothelial cell, and
fibroblast populations demonstrated significantly improved
biocompatibility of neutral pH, bicarbonate/lactate-based so-
lutions compared to conventional solutions. The solutions
contributed to improved leukocyte viability and response to
bacterial infection (e.g., phagocytosis, superoxide radical gen-
eration, and endotoxin-stimulated cytokine release). Studies
on peritoneal mesothelial cells demonstrate improved cell via-
bility, proliferation, and response to proinflammatory stimuli,
and a reduced potential for angiogenesis and peritoneal fibro-
sis, all suggesting a better preservation of membrane structure
and function. The bicarbonate/lactate-based solutions demon-
strated decreased cytotoxicity and preserved cell growth in
fibroblast cultures as well. In vitro biocompatibility testing
has clearly demonstrated that neutral pH, bicarbonate/lactate-
buffered Physioneal solutions are superior to conventional
solutions in preserving cell viability and function in cell popu-
lations that contribute to peritoneal homeostasis. This positive
assessment now provides a foundation and rationale for mov-
ing forward with the next stages in preclinical testing: in vivo
animal models and human ex vivo studies.
Peritoneal dialysis (PD) has been a successful and
effective form of chronic renal replacement therapy since
it was introduced over 20 years ago. Despite its over-
all success, technique survival can be compromised by
complications of peritonitis and alterations in membrane
physiology that occur in some patients with time on dial-
ysis, leading to peritoneal fibrosis, increased membrane
permeability, and eventual ultrafiltration failure. The con-
tinued success of PD as a long-term treatment option
Key words: in vitro biocompatibility, bicarbonate/lactate-buffered
solutions, peritoneal dialysis.
C© 2003 by the International Society of Nephrology
depends, therefore, on minimizing peritonitis and pre-
serving the overall structure and function of the
membrane.
There is a growing body of evidence that suggests
that, while the conventional PD solutions perform well
in terms of metabolic waste removal and maintenance of
fluid and electrolyte balance, there are shortcomings in
terms of their ability to preserve membrane integrity and
longevity that appear to be associated with components
of the solutions themselves. This realization has led to the
development of several second-generation PD solutions
that demonstrate improved biocompatibility. Physioneal,
a neutral pH, bicarbonate/lactate-buffered solution, was
one of the first of these new PD solutions to become com-
mercially available.
This review will focus on one of the first preclinical
stages in the development of Physioneal: studies on in
vitro biocompatibility. The role that these studies play in
formulation development, their intrinsic advantages and
disadvantages, an overview of the studies, the knowledge
gained from them, and finally, whether these studies are
ultimately predictive of in vivo solution performance will
be discussed.
OVERVIEW OF BIOCOMPATIBILITY
The biocompatibility of a PD solution can be defined
as the ability of the solution formulation to support long-
term dialysis without causing clinically significant changes
in the functional characteristics of the membrane. More
specifically, the solution must support the dialytic func-
tions of both fluid balance and waste removal while pre-
serving membrane physiology. Qualities of PD solutions
thought to affect biocompatibility include solution pH,
buffer components, osmolality, glucose concentration,
and the glucose degradation product (GDP) profile.
The potential effects of biocompatibility factors on
clinical outcomes are illustrated in Figure 1. Solution
components can affect the normal physiology of the
cell populations of the peritoneal cavity (e.g., leukocyte,
mesothelial and endothelial cell, and fibroblast popula-
tions), resulting in alterations in cytokine, chemokine,
and growth factor networks, upregulation of proin-
flammatory and profibrotic pathways, and induction of
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PD solution biocompatibility factors
Inhibition of normal leukocyte, mesothelial, endothelial, and fibroblast function
Alteration of cytokine, chemokine, and growth factor networks
Disturbances in inflammatory and fibrotic mediators
Cross-linking of structural proteins
Carbonyl and oxidative stress
Impaired peritoneal
host defense
Temporal changes in peritoneal
structure and function
Altered peritoneal permeability;
Altered ultrafiltration
Ultrafiltration failure
Fig. 1. Potential role of biocompatibility in
clinical outcomes. Chronic exposure to bioin-
compatible peritoneal dialysis (PD) solu-
tions can result in perturbations in normal
peritoneal membrane physiology. Over time,
these changes in membrane structure and
function can contribute to altered transport
characteristics, peritoneal fibrosis, and scle-
rosis, and ultimately to ultrafiltration failure
and discontinuation of PD therapy. Reprinted
with permission from reference [122].
carbonyl and oxidative stress. These perturbations in nor-
mal membrane physiology are thought to contribute to
impaired host defense, changes in peritoneal structure
including peritoneal fibrosis and vasculopathy, and
changes in dialytic functions, including increased solute
permeability and ultrafiltration failure. The importance
of each of these biocompatibility factors and their hypoth-
esized roles in cellular and membrane dysfunction has
been extensively reviewed [1–3]. This article will briefly
discuss each of these factors and focus on their relative
contributions to the Physioneal solution formulation and
biocompatibility.
PHYSIONEAL PD SOLUTION
PD solutions were originally intended to be formu-
lated with bicarbonate, as it is a physiologically rele-
vant buffer. However, due to technological challenges in
manufacturing a stable bicarbonate-based PD solution,
the first commercially available solutions were acetate-
or lactate-based. The advent of solution sterilization in
multichambered bags facilitated the commercial devel-
opment of bicarbonate-based solutions because they par-
tition glucose at low pH in one chamber, which minimizes
heat-catalyzed degradation, while keeping the bicarbon-
ate component in a separate chamber at an alkaline pH.
Mixing the two chambers just prior to use provides the
means to deliver bicarbonate-based, glucose-containing
Table 1. Composition of Physioneal and Dianeal formulations
Component Dianeal PD-4 Physioneal 40
Lactate mEq/L 40 15
Bicarbonate mmol/L — 25
pH 5.2 7.4
Glucose g/L 13.6, 22.5, 38.6 13.6, 22.5, 38.6
Osmolality mOsm/kg 358, 401, 511 358, 401, 511
Sodium mEq/L 132 132
Chloride mEq/L 95 95
Magnesium mEq/L 0.5 0.5
Calcium mEq/L 2.5 2.5
solutions at neutral pH. Physioneal PD solutions differ
from first generation low pH, lactate-buffered fluids such
as Dianeal, as they use 25 mmol/L bicarbonate combined
with 10 to 15 mmol/L lactate as the buffer, and are for-
mulated for delivery at a neutral pH (Table 1). While
Physioneal solutions are formulated with the same glu-
cose concentrations as Dianeal, and therefore have the
same osmolarities, this new container system has resulted
in significantly lower levels of potentially cytotoxic GDPs
(Table 2). How do these changes—neutral pH, bicarbon-
ate/lactate buffer and low GDPs—result in improved so-
lution biocompatibility?
ASPECTS OF BIOCOMPATIBILITY
In order to fully evaluate how the Physioneal for-
mulation results in improved biocompatibility, we first
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Table 2. Comparison of glucose degradation product concentrations in Dianeal and Physioneal
Compound Methylglyoxal Glyoxal 3-Deoxyglucosone
lmol/L
% Glucose Dianeal Physioneal Dianeal Physioneal Dianeal Physioneal
1.36% 2.05 ± 0.56 0.59 ± 0.28 2.17 ± 0.27 2.24 ± 0.46 97 ± 13.5 70 ± 6.6
2.27% 2.71 ± 0.19 0.8 ± 0.15 2.96 ± 0.51 2.49 ± 0.58 164 ± 6.1 111 ± 5.7
3.86% 4.08 ± 0.86 1.12 ± 0.03 3.13 ± 0.28 3.3 ± 0.61 298 ± 48 161 ± 14.1
The GDP profile was obtained from Dawnay et al: J Am Soc Nephrol 10:312A, 1999.
need to understand the effect of the individual so-
lution components on normal cellular structure and
function.
Low pH and elevated lactate
The first-generation PD solutions were based on a pH
5.2, 40 mmol/L lactate formulation. It has been exten-
sively documented that this combination of acidic pH,
well below physiologic pH of 7.4 and superphysiologic
levels of lactate, is inhibitory to a number of cell func-
tions in vitro, and is therefore a primary determinant of
PD solution bioincompatibility.
The cytotoxicity of low pH, lactate-based solutions
appears to be primarily due to the profound drop in intra-
cellular pH (pHi) that occurs almost immediately upon
exposure to fresh PD solution. Duwe et al [4] were the
first to document a reduction in phagocytosis, bacteri-
cidal capacity, and respiratory burst in neutrophils upon
exposure to commercial PD solutions. Similarly, exposure
of PMφ to conventional dialysate resulted in impaired
chemiluminescence, a decreased capacity for oxygen rad-
ical generation, and a decline in bacterial cell killing [5].
While the decline in pHi is most severe in the presence of
both low pH and high lactate, intracellular acidification
and impaired respiratory burst in PMφ were also noted
at pH 6.5 and 7.0, indicating that the effect is at least
partially independent of pH [abstract: Chaimovitz et al,
J Am Soc Nephrol 3:407A, 1992]. A slightly different out-
come was noted by Liberek et al [6], who found that while
PMφpHi and chemiluminescence were reduced upon ex-
posure to low pH, lactate-containing fluids, they were not
significantly altered in lactate-containing neutral pH so-
lutions. Increasing lactate concentration resulted in de-
creased phagocytic activity in polymorphonuclear cells
(PMN) at both acidic and neutral pH, although the
inhibition was much more severe at pH 5.2, while cell
viability and leukotriene B4 generation were not sig-
nificantly changed from control under these conditions.
Topley et al [7] demonstrated decreased chemilumines-
cence in macrophages only in the presence of both factors,
as lowering the pH of culture media to 5.2, or increasing
the lactate content at neutral pH, had no effect. Finally,
improved neutrophilic superoxide production was noted
in lactate-based solutions when the pH was neutralized
[8].
The combination of acidic pH and lactate in con-
ventional peritoneal dialysis fluids (PDF) also adversely
affected cytokine release from endotoxin-stimulated
leukocytes. Jo¨rres et al [9] demonstrated a decrease in
interleukin (IL)-6 and tumor necrosis factor a (TNFa)
release from mononuclear leukocytes, and Douvdevani
et al [10, 11] found that inhibition of IL-1 and TNFa re-
lease was maximal at low pH and high lactate, minimal
with lactate at neutral pH, and unaffected by pH alone.
While the specific effects of low pH, lactate-based solu-
tions appear to vary by cell type and individual parameter
under investigation, there is a consensus that exposure to
these solutions has a rapid and negative impact on cellular
function.
Because dialysis solution equilibrates upon infusion,
with pH reaching 6.8 within 30 minutes and near physio-
logic pH within 120 minutes, the recovery of cell func-
tion after initial exposure to PDF was examined in a
number of in vitro studies. Neutrophils reportedly failed
to generate a respiratory burst after a one-hour recov-
ery period in normal media, even though pHi had been
restored [12]. Recovery of function in PMφ was delayed
as well, with the failure of pHi, cytoskeletal alterations,
proinflammatory cytokine release, and phagocytosis to
return to normal levels [13–15]. It would appear that the
low pH, lactate combination has a significant impact not
only on cell function but on recovery of function as well.
Witowski et al [16] reported that exposure of hu-
man peritoneal mesothelial cells (HPMC) to standard
PD solutions resulted in an inhibition of IL-6 and
prostaglandin E2 (PGE2) release that appeared to be
related to low pH. Low pH/high-glucose media had an
inhibitory effect on fibrinolytic parameters in HPMC,
with the effect of low pH stronger than that due to high
glucose/hyperosmolality [17]. Lactate has been shown to
modulate glucose-mediated effects on cellular function,
potentially through enhancement of intracellular sorbitol
accumulation [18, 19]. A recent study in HPMC suggests
that exposure to glucose in the presence of lactate leads
to an increase in TGF-b and monocyte chemoattractant
protein-1 (MCP-1) to levels above those induced by glu-
cose or lactate alone, possibly via enhanced activation of
the polyol pathway and sorbitol accumulation [20]. While
the degree of cellular impairment varies with cell type
and functional parameter under evaluation, there is a
consensus that the combination of low pH and lactate
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compromises both host defense and physiologic functions
of the membrane and its cellular components.
Glucose
Glucose has been used successfully as the sole
osmotic agent in PD solutions for over 20 years. There
is growing concern, however, regarding the long-term
effect of chronic exposure of peritoneal tissues and cells
to superphysiologic levels of glucose and the impact on
peritoneal physiology. Various aspects of glucotoxicity—
mechanisms by which glucose can adversely affect mem-
brane structural and functional parameters—have been
extensively reviewed [3, 21–23] and will be briefly sum-
marized here.
In assessing mechanisms of glucotoxicity, it is impor-
tant to consider not only the direct effects of glucose on
cellular parameters, but also how glucose may indirectly
influence cell functions through hyperosmolality and
glucose degradation production (GDP)- and advanced
glycation end product (AGE)-mediated reactions.
Glucose-based solutions are hyperosmolar relative to
normal serum (358 to 511 mOsm vs. 280 mOsm) and a
number of studies have shown negative effects of glucose
and/or hyperosmolality on cellular function. In HPMC,
the generation of reactive oxygen species, upregulation
of the polyol and p38 MAPK pathways, enhanced expres-
sion of genes such as transforming growth factor-beta
(TGF-b), fibronectin, laminin, and MCP-1, increased
apoptosis, and increased oxidative mitochondrial dam-
age have all been noted after exposure to high glucose
[3, 21, 22, 24–32]. In a recent study, Tamura et al [33]
found that high glucose (140 mmol/L), and to a lesser
extent, high osmolality, inhibited mesothelial cell migra-
tion. This effect on migration, combined with glucose-
mediated damage to intercellular junctions [34], suggests
how chronic exposure to high glucose PDF could promote
membrane damage by interfering with remesothelializa-
tion of the membrane after injury. Increased expression
of PGE2 [35], tissue plasminogen activator (tPA) [36], and
aquaporin-1 (AQP-1) [37, 38] in mesothelial cell popula-
tions appeared to be largely due to hyperosmolality.
The effects of high glucose/hyperosmolality have also
been documented in leukocyte populations and include
reductions in cell viability, phagocytosis, bactericidal
activity, respiratory burst, and superoxide and cytokine
production [6, 39–42]. Finally, the rate of fibroblast pro-
liferation was altered in the presence of glucose, with
an initial increase in cell number followed by a decrease
at later timepoints [43]. The synthesis of procollagen III
peptide (PIIIP) was also increased in these cells, as was
the production of hyaluronan through enhanced protein
kinase C activity [44, 45], indicating a potential glucose
effect on expansion of the extracellular matrix and inter-
stitial space. Finally, the synthesis of vascular endothe-
lial growth factor (VEGF) by rat peritoneal vascular
endothelial cells, and its upregulation by high glucose,
lactate-based PDF indicates the potential for dialysis-
mediated changes in the vasculature and membrane
permeability [46]. Increased expression of VEGF in en-
dothelial cells could contribute to an increased effective
peritoneal surface area, increased permeability to glucose
and small solutes, and potentially predispose the mem-
brane to ultrafiltration failure [47].
In summary, glucose and hyperosmolarity have the po-
tential to adversely affect normal leukocyte, mesothelial,
and fibroblast physiology. These factors could enhance
processes of inflammation, angiogenesis, peritoneal
fibrosis, extracellular matrix (ECM) expansion, and cellu-
lar damage, all contributing factors to compromised host
defense, decreased cell viability, profibrotic changes in
the membrane. The end result may be altered peritoneal
transport and ultrafiltration failure.
Glucose degradation products
Glucose degradation products have received increased
scrutiny regarding their contribution to PD solution
bioincompatibility and membrane dysfunction. These
low molecular weight compounds are formed primarily
from the breakdown of glucose during heat sterilization,
but can also form during storage of glucose-containing
solutions. GDPs include acetaldehyde, formaldehyde,
2-furaldehyde, 5-hydroxymethyl-furfural, glyoxal,
methylglyoxal (MG), 3-deoxyglucosone (3-DG), and
the recently identified 3,4-dideoxyglucosone-3-ene
(3,4-DGE)[48], as well as compounds not yet chemically
identified [49–51]. GDPs exert their effects via two
mechanisms: directly, by affecting cell viability and cell
function (e.g., cell proliferation, gene expression), and
indirectly through increased carbonyl and oxidative
stress, and by contributing to the formation of AGEs and
advanced lipoxidation end products (ALEs).
In vitro cell culture studies have demonstrated GDP
cytotoxicity in a variety of cell types. Conventional heat-
sterilized PD solutions inhibited cell growth in L-929 cells,
an established fibroblast cell line, to a significantly greater
degree than did the comparable filter-sterilized solutions
[49]. These results were confirmed in different cell pop-
ulations, with an inhibition of cellular proliferation and
TNFa release in an established murine macrophage line,
and diminished capacity for superoxide radical gener-
ation in freshly prepared human leukocytes [52]. The
acceleration of apoptosis in peripheral neutrophils was
proposed to be due to GDPs in conventional, glucose-
based PD solutions [53], as the effect was independent of
lactate and osmolarity, and reduced upon exposure to low
GDP-containing bicarbonate/lactate-based solutions.
In HPMC, long-term exposure (i.e., 36 days)
of cells to a mixture of GDPs (acetaldehyde,
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formaldehyde, 2-furaldehyde, glyoxal, MG, and
5-hydroxymethylfuraldehyde) at the concentrations
found in high glucose conventional PDF led to a sig-
nificant impairment of cell viability and function [54].
The authors noted a decreased proliferative capacity,
reduced constitutive and interleukin-1 (IL-1)-stimulated
expression of IL-6, decreased secretion of fibronectin,
and impaired cellular attachment to substrates, the latter
suggesting an effect on wound-healing capacity. These
same authors had previously concluded that short-term
exposure (e.g., 24 hours) to individual GDPs had no
effect, and only in combination was a subtoxic effect
seen [55], pointing out the importance of exposure time
in evaluating potential effects in vitro. In contrast, an
effect of individual GDPs on HPMC cellular parameters
was demonstrated in a recently published study. Welton
et al [56] showed an uptake of 3-DG and MG by HPMC,
resulting in the formation of early AGEs. A short
exposure to individual GDPs resulted in an increased
proinflammatory response as evidenced by induction
of vascular cell adhesion molecule-1 (VCAM-1) and
elevated production of IL-6 and IL-8. In addition, both
3-DG and MG induced apoptosis and reduced cell
proliferation [56]. In HPMC, the upregulation of heat
shock protein-72 (HSP-72), an indicator of cellular
stress, appeared to be due to acidic pH and GDPs in
a standard PDF; HSP-72 expression was significantly
reduced in neutral pH, low GDP solutions [57]. Finally,
a recent study in L-929 fibroblasts showed that of all the
identified GDPs, only 3,4-DGE was inhibitory to cellular
proliferation at concentrations found in conventional
PDF, leading the authors to suggest that 3,4-DGE was
the most biologically active of all GDPs [48].
The manufacturing of Physioneal in multichamber bags
has resulted in a reduction in GDPs compared to con-
ventional solutions, implying a decreased potential for
GDP-mediated cellular and membrane alterations. This
reduction is significant, especially for patients requiring
high glucose solutions to achieve adequate ultrafiltration,
as GDP levels in 3.86% Physioneal are either below or
equivalent to levels in 1.36% Dianeal (Table 2).
Advanced glycation end products
Glucose can also contribute indirectly to membrane al-
terations and compromised membrane function through
the formation of AGEs. These compounds are formed
when reducing sugars such as glucose, or reactive car-
bonyl compounds (RCOs) such as GDPs, react nonenzy-
matically with amino groups of proteins to form a Schiff
base, which can then undergo an irreversible reaction to
form AGEs. AGEs and their lipid counterparts, ALEs,
have been implicated in a variety of activities that can ad-
versely affect the peritoneal membrane, including protein
and ECM crosslinking, inflammation, angiogenesis [58],
vascular smooth muscle cell proliferation [59], and in-
creased nitric oxide production [60]. Peritoneal biopsies
from long-term PD patients show pathologic alterations
that are strikingly similar to those of patients with dia-
betiform disease, with thickening of the basement mem-
brane, vascular alterations, and AGE deposition [61–64],
implicating exposure to glucose and/or its degradation
products in membrane pathogenesis. A recent histochem-
ical analysis of peritoneal membrane biopsies has demon-
strated a colocalization of AGEs with TGF-b , VEGF, and
M-CSF, suggesting that AGE-receptor binding activates
signaling pathways leading to the expression of growth
factors and development of peritoneal fibrosis [65]. These
observations, when taken together with patient clinical
data, suggest a correlation between time on dialysis, peri-
toneal tissue AGE content, and membrane dysfunction
[64, 66].
Several in vitro studies support a link between AGE
modification and alterations in cellular function. A study
in human microvascular endothelial cells indicated that
AGEs stimulated VEGF production [67], an associa-
tion that could have a significant impact on peritoneal
membrane permeability. Rashid et al [68] have demon-
strated that exposure of rat PMφ to AGE-modified serum
albumin resulted in increased levels of both constitu-
tive and endotoxin-stimulated TNFa under conditions
where glucose had no significant effect. In HPMC, AGEs
were shown to stimulate VCAM-1 expression [69] and
reduce viability in vitro in a dose-dependent fashion
[70]. Finally, Amadori modified, or early glycated albu-
min, increased plasminogen activator inhibitor-1 (PAI-1)
expression in HPMC [71], indicating how glycation of
proteins may directly contribute to the fibrinolytic im-
balance seen in PD patients. Taken together, these
studies provide an indication of how AGEs can affect
a variety of (patho)physiologic processes in peritoneal
cell populations, all potentially contributing to membrane
dysfunction.
A study by Millar et al [72] demonstrated that a neutral
pH, bicarbonate/lactate-based solution has significantly
reduced potential for AGE formation in vitro (Fig. 2). The
lower rate and degree of AGE formation over time com-
pared to lactate-based solutions of corresponding glucose
content is probably due, at least in part, to a decreased
formation of GDPs during sterilization and not to glu-
cose per se. This suggests that bicarbonate/lactate-based
solutions have a decreased potential for AGE formation
in vivo, which would minimize membrane damage and
preserve membrane structure and function.
OVERVIEW OF BIOCOMPATIBILITY TESTING
This section will focus on the role of preclinical biocom-
patibility testing as an integral part of PD solution devel-
opment. Biocompatibility testing should ideally follow a
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Fig. 2. In vitro advanced glycation end product (AGE) formation with
standard and bicarbonate/lactate solutions. Increase in human serum
albumin–associated fluorescence following incubation in either stan-
dard lactate-buffered (L) or bicarbonate/lactate-buffered (B/L) peri-
toneal dialysis (PD) fluids containing either 1.36% or 3.86% glucose.
Fluorescence is in arbitrary units per gram of hyaluronan synthase
(HAS)/L. Symbols are: () 1.36% B/L, () 3.86% B/L, () 1.36% L,
( ) 3.86% L. Reprinted from reference [72] with permission from Adv
Perit Dial.
hierarchical approach as previously suggested by Holmes
[73, 74] in this supplement. This review will focus on the
first stage of this process, in vitro biocompatibility test-
ing, while the other stages are reviewed elsewhere in this
Kidney International supplement.
In vitro biocompatibility testing
The cell culture–based assay is the primary test sys-
tem of in vitro biocompatibility testing, and can be
designed to ask specific, physiologically relevant ques-
tions concerning the biological effects of solutions and/or
solution components. One of the advantages of this type
of testing is that it can focus on specific molecular path-
ways in distinct homogeneous cell populations. Inherent
in this approach, however, is that it obviously does not,
and cannot, duplicate the in vivo environment, and there-
fore does not capture the multifactorial interactions and
molecular crosstalk that occurs in vivo. With this short-
coming in mind, these studies should be as representa-
tive of the in vivo environment as possible, and should
include testing of all relevant cell populations and cellu-
lar functions that can affect the dialytic properties of the
membrane.
There are a number of considerations in the design of
experiments for in vitro biocompatibility testing. These
include the selection of cell populations, identification of
relevant functional parameters, and experimental design
(see [73] for a detailed review).
Cell populations
In choosing cell populations for in vitro biocompatibil-
ity testing, it is important to consider each cell type that
plays a role in maintaining peritoneal cavity physiology
and that is exposed to dialysis solutions or solution com-
ponents. The cell populations examined in these studies
should therefore include peritoneal and peripheral leuko-
cytes, peritoneal mesothelial cells, peritoneal fibroblasts,
and the endothelial and vascular smooth muscle cells of
the peritoneal vasculature. The suitability of using estab-
lished or immortalized cell lines versus primary cultures
in these studies has been questioned. The general consen-
sus seems to favor the use of primary cultures; although
established cell lines are more readily available and more
adapted to cell culture, primary cultures may be more
physiologically representative of the in vivo environment
and response.
Assay parameters
In vitro biocompatibility testing should focus not only
on basic parameters such as cell viability, proliferation,
and on functions associated with peritoneal homeosta-
sis, but also on involvement of pathogenic processes
that may influence clinical outcomes and membrane dys-
function. The peritoneal cell populations and poten-
tial assay parameters are described below and listed in
Table 3.
Peripheral and peritoneal leukocytes. Peritoneal and
peripheral leukocytes have been used extensively in
in vitro testing. Leukocytes have been obtained from
peripheral blood of healthy volunteers, peritoneal
macrophages from nonuremic patients undergoing
laproscopy, and peritoneal macrophages and neutrophils
isolated from the effluents of continuous ambulatory
peritoneal dialysis (CAPD) patients. The use of effluent-
derived cells that have been exposed to PD solutions
raises questions about preconditioning or activation, and
how that may influence subsequent testing. It should not
preclude the use of these cells, but their origin should be
factored into any interpretation of the results.
Resident and circulating leukocytes perform a variety
of functions depending on their cell type. They act as the
first line of host defense in the peritoneal cavity, and in-
teract with the mesothelial cell and fibroblast populations
through the production of various signaling molecules. A
large body of evidence has shown that conventional PDF
markedly suppresses functional capabilities of periph-
eral blood leukocytes and PMφ. Therefore, parameters
such as phagocytosis, bacterial cell killing, and production
of reactive oxygen species should be routinely tested as
indicators of biocompatibility in these cells.
Peritoneal mesothelial cells. Peritoneal mesothelial cells
have also been extensively used in in vitro biocompati-
bility testing. Mesothelial cells are isolated from omental
tissue of consenting patients undergoing elective surgery,
expanded in cell culture, and generally used within the
first several passages. HPMC have also been isolated from
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Table 3. Peritoneal cell populations and assay parameters
Cell type Assay parameter Function
Leukocytes Proliferation (N, M)
LDH release, ATP content
(N, M)
pHi (N, M)
Cell viability
Phagocytosis (N, M)
Bactericidal activity (N, M)
Respiratory burst/
chemiluminescence
Superoxide production (N)
Cytokine expression (M
Host defense
IL-1, TNFa, IL-8, TGF-b Inflammatory signaling
Mesothelial
cells
Proliferation
Oxidative damage
Apoptosis
Cell viability
Migration Tissue repair, wound
healing
Cytokine and growth factor
expression:
IL-1, IL-6, MCP-1,
RANTES, PGE2, PGI1,
Host defense
tPA, PAI-1, TF, MMPs,
TIMP
Coagulation, fibrinolytic
balance
TGF-b , CTGF, fibronectin,
laminin, PIIINP, PIICP,
collagen
ECM deposition, tissue
repair
VEGF
Aquaporins
Angiogenesis, vascular
permeability, water
transport
HSP-72 Stress response
HA, GAGs Lubrication
Fibroblasts Proliferation Cell viability
Transdifferentiation to
myofibroblasts
Tissue repair, response to
injury and inflammation
Leukocyte trafficking Response to inflammation
HA
PICP [119],
PIIINP [120]
Tissue repair, ECM
expansion
Endothelial
cells
Proliferation Cell viability
VEGF, VEGFr Angiogenesis
Aquaporin expression Water transport
eNOS, iNOS NO signaling
Abbreviations are: N, polymorphonuclear neutrophils; M, monocytes,
macrophages; LDH, lactate dehydrogenase; pHi, intracellular pH; IL-1,
interleukin-1; TNFa, tumor necrosis factor a; IL-6, interleukin-6; IL-8,
interleukin-8; TGF-b , transforming growth factor-b ; MCP-1, monocyte chemoat-
tractant protein-1; RANTES; regulated upon activation, normal T cell ex-
pressed and secreted; PGE2, prostaglandin E2; tPA, tissue plasminogen activator;
PAI-1, plasminogen activator inhibitor-1; MMP, metalloproteinase; TIMP, tissue
inhibitor of metalloproteinases; TGF-b , transforming growth factor b ; CTGF,
connective tissue growth factor; PIIINP, procollagen III peptide; PIICP, procol-
lagen type II carboxyterminal propeptide; VEGF, vascular endothelial growth
factor; VEGFr, VEGF receptor; HSP-72, heat shock protein-72; HA, hyaluro-
nan; GAG, glycosaminoglycan; ECM, extracellular matrix; PICP, procollagen I
C-terminal peptide; eNOS, endothelial nitric oxide synthase; iNOS, inducible ni-
tric oxide synthase; NO, nitric oxide.
peritoneal effluent, but these are probably best suited for
immediate phenotypic characterization.
Mesothelial cells play an active role in peritoneal mem-
brane physiology. They maintain a fibrinolytic balance in
the peritoneal cavity with the production of fibrinolytic
and coagulant molecules [75–78], participate in mem-
brane repair and remodeling [79–85], are active in host
defense and response to inflammation with the produc-
tion of a variety of cytokines, chemokines, and growth
factors [29, 35, 86–91], and affect peritoneal transport
through the production of molecules that have a direct
effect on the vasculature [37, 92–96]. The mesothelial cell
parameters assayed in biocompatibility studies should
therefore include measures of mesothelial cell health,
fibrinolytic and coagulant activity, host defense, tissue
repair, and angiogenesis.
Peritoneal fibroblasts. Peritoneal fibroblasts can also be
isolated from omental tissue and established in cell cul-
ture. There has been considerably less biocompatibility
testing in primary fibroblasts as compared to leukocytes
and mesothelial cells to date, although solution biocom-
patibility has been evaluated in murine L-929 cells, an
established fibroblast cell line.
Peritoneal fibroblasts are involved in response to in-
flammation and leukocyte trafficking, and contribute
to membrane structure through the synthesis of ECM
components, and participate in tissue repair and wound
healing. Cell proliferation is increased in cultured fibrob-
lasts in response to the proinflammatory cytokines IL-1
and TNFa, as is the synthesis of prostaglandins PGE2
and PGI1 [97], chemokines and cytokines such as MCP-
1, IL-6, and IL-8 [98, 99], and ECM components and
glycosaminoglycans such as hyaluronan [45, 97, 100].
Proliferation of fibroblasts and their conversion to a my-
ofibroblast phenotype, a prelude to developing a profi-
brotic state, has been observed upon repeated exposure
to infected PD effluent [101], and may be enhanced by
chronic exposure to glucose and/or GDPs and AGEs.
Biocompatibility testing in fibroblasts should include in-
dicators that are reflective of maintaining the normal
fibroblast physiology, response to infection, and tissue
repair.
Endothelial cells. Peritoneal endothelial cells and vas-
cular smooth muscle cells comprise and dictate the struc-
tural and functional characteristics of the peritoneal
vasculature, and like mesothelial cells and fibroblasts, can
be isolated from omental tissue. Capillary endothelial
cells perform a number of functions, including regula-
tion of angiogenesis and vessel permeability through the
expression of VEGF and VEGF receptors, and aquapor-
ins or water channels equivalent to the ultrasmall pores
of the peritoneum. The production of nitric oxide by
endothelial nitric oxide synthase (eNOS) and inducible
nitric oxide synthase (iNOS) is thought to play a signif-
icant role in the regulation of peritoneal permeability
[102, 103] and in the induction of angiogenesis. Biopsy
studies from long-term PD patients have revealed an
increased number of vessels per area, vascular wall thick-
ening in small arteries, and capillary vasodilatation [104]
and increased expression of eNOS in the vasculature [60],
suggesting that changes in endothelial cell physiology
contribute to declining peritoneal transport and even-
tual ultrafiltration failure. Evaluation of markers of vas-
cular permeability and angiogenesis would therefore be
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recommended for biocompatibility testing in endothelial
cells.
The cellular parameter(s) selected for assay will
depend on the solution component being investigated
and the cell population being tested. For example, it
is physiologically relevant to assay pHi in PMNs be-
cause of acute exposure upon instillation of PD solution
in vivo, but not practical to assay in fibroblasts because
they are not directly exposed to solution. The effect of
GDPs on mesothelial cell function should be assayed be-
cause these cells are directly and chronically exposed to
solution. The effects should be evaluated in fibroblasts
and endothelial cells as well. Even though these cells are
not in direct contact with solution, it is known that GDPs
are transported from the peritoneal lumen across the
membrane into the interstitium [105–107], thereby mak-
ing fibroblasts and endothelial cells vulnerable to GDP-
and AGE-mediated modifications.
Experimental design
Once both the cell population and functional pa-
rameter to be investigated are chosen, studies must be
designed to be as representative as possible of in vivo
conditions. One aspect to consider in experimental de-
sign is time of exposure to the solution under evaluation.
A short exposure time, for example, up to 60 minutes, may
be suitable to measure a rapid response, such as changes
in pHi and host defense characteristics. Jo¨rres [108] has
recommended exposure times of less than 30 minutes to
undiluted solutions to determine the effects of pH and
buffer components, and times of less than 4 hours to ex-
amine the effects of osmolarity. Evaluation of changes in
gene expression may require longer periods of exposure
(e.g., 24 to 72 hours) in order for changes in mRNA or
protein levels to become detectable.
Whether or not the test solution should be diluted
with culture medium is also a consideration. For acute,
short-term exposures of less than 30 minutes, the use of
undiluted solution may be acceptable. This is also ap-
propriate for exposure/recovery studies in which cells
are transferred from a short incubation in test solution
into normal culture medium. The functional parameter
may be then assayed directly, or a specific stimulus (e.g.,
endotoxin, cytokine) added and cellular response moni-
tored. A short, acute exposure would be appropriate for
evaluating the effect on intracellular pHi and response
to endotoxin challenge. It is well known that PD solu-
tion undergoes a rapid equilibration upon instillation into
the peritoneal cavity, with neutralization of pH, dilution
with residual solution, and absorption of glucose over
time, so it is unrealistic to conduct longer-term incuba-
tions in undiluted solutions. On a practical note, cells that
normally obtain their nutrients from the interstitial fluid
need an exogenous supply of nutrients to maintain basic
growth parameters over longer periods of time, and it is
becoming the standard practice in long-term experiments
to dilute dialysis solutions two-fold with serum-free or
low serum culture medium.
Another type of study that is appropriate for experi-
mental testing involves the use of preconditioned media.
In this system, one cell population is exposed to the test
solution, the supernatant collected, and then transferred
to a second culture of the same or different cell type,
and response monitored. This experimental design allows
evaluation not only of the effects of solution but also the
effects of the factors produced in response by the first
cell population. For example, leukocyte or mesothelial
cells could be exposed to the test solution, their super-
natants collected and transferred to fibroblast cultures,
and the effect(s), such as changes in gene expression,
assayed. In this scenario, the fibroblasts are exposed not
only to the solution components, but to factors produced
by the leukocytes and mesothelial cells. This type of study
recognizes the importance of secondary cell signaling and
attempts to duplicate the cross-talk between cells and cell
populations. It is probably also more indicative of the in
vivo situation where a cell type may respond only mini-
mally to a component of the PD solution, but exhibit a
much more significant response to factors produced by
other cell populations.
Cell culture systems have been described that are more
representative of in vivo conditions than the traditional
growth in two-dimensional cultures. Beavis et al [101]
have described a unique cell culture system in which
fibroblasts are grown in a three-dimensional collagen ma-
trix, a system that better reflects the in vivo environment
than the traditional two-dimensional cell culture. Cell
culture media and supernatants can be added directly
to these cultures and responses such as proliferation,
cytokine and growth factor secretion, and migration
monitored.
IN VITRO BIOCOMPATIBILITY STUDIES
ON BICARBONATE/LACTATE SOLUTIONS
The studies examining the biocompatibility of
bicarbonate/lactate-based solutions are listed in Table 4
and reviewed below.
Studies with leukocyte populations
A study by Rogachev et al [109] was the first to exam-
ine the biocompatibility of bicarbonate/lactate- and pure
bicarbonate–buffered solutions in PMφ. Cells were iso-
lated from the overnight effluent of CAPD patients who
had been peritonitis free for the previous six months,
and the effects of the solutions on pHi and cytokine
production measured. Upon exposure to 1.5% Dianeal
(1.5-D), the pHi dropped sharply to below 6.2; however,
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Table 4. In vitro biocompatibility studies outcomes
Bioincompatible
Cell type Lactate/Dianeal Bicarbonate/Lactate factor Reference
Peritoneal Decreased pHi < 6.2 Maintained pH 6.6–6.8 pH [109]
macrophage
Reduced endotoxin-stimulated Improved TNFa release pH [109]
TNFa release
PMN Decreased cell viability No change pH [110]
Decreased chemiluminescence No change pH [110]
Decreased phagocytosis to Decreased phagocytosis to pH [110]
<20% of control 40–55% of control
Decreased superoxide generation Improved superoxide generation GDPs [111]
Decreased phagocytosis Improved phagocytosis GDPs [111]
PBMC Decreased TNFa secretion Improved TNFa secretion GDPs [111]
HPMCs Decreased cell viability Improved cell viability pH [110]
Decreased cell viability Improved cell viability pH; secondary effect [113]
of GDPs
Increased DNA damage No effect pH, lactate [113]
Decreased proliferation Improved proliferation Osmolarity [113]
Decreased proliferation Improved proliferation [121]
Decreased IL-6 No effect pH [110]
Increased VEGF Increased VEGF GDPs [114]
Increased TGF-b No change GDPs [114]
Increased PIIINP Increased PIIINP GDPs [114]
Fibroblasts Decreased proliferation Improved proliferation GDPs [115]
pHi, intracellular pH; TNFa, tumor necrosis factor a; GDP, glucose degradation product; IL-6, interleukin-6, VEGF, vascular endothelial growth factor; TGF-b ,
transforming growth factor-b ; PIIINP, procollagen III N-terminal peptide.
adjustment of Dianeal to pH 7.3 prior to testing main-
tained the pHi between 6.6 and 6.8. Exposure to a 1.5%
25 mmol/L bicarbonate/15 mmol/L lactate solution, pH
7.3 (1.5-B/L) reduced pHi relative to the control medium,
but it remained above pH 6.5 for the duration of the as-
say. Having demonstrated that the neutral pH, bicarbon-
ate/lactate formulation prevented a drastic decline in pHi,
the authors examined whether other previously noted ad-
verse effects of standard solutions were alleviated. Secre-
tion of TNFa in response to an endotoxin challenge was
selected as a representative cellular parameter and in-
dicative of PMφ participation in host defense.
PMφ were exposed to test solutions for 15 to 30 min-
utes, then transferred to growth medium, challenged
with lipopolysaccharide (LPS), and TNFa secretion mea-
sured. 1.5-D reduced TNFa production by 59% and by
>95% at 15 and 30 minutes, respectively, compared to
control medium (Fig. 3). 1.5-B/L improved PMφ response
at both time points with a significant change from control
only at 30 minutes. TNFa secretion in bicarbonate/lactate
solutions containing 4.25% dextrose decreased compared
to 1.5% at both times, but the levels were still improved
over those of 1.5-D at 15 minutes. This study suggests that
bicarbonate/lactate-buffered solutions are more biocom-
patible with regards to PMφ function, maintaining pHi
closer to physiologic levels and preserving cytokine se-
cretion in response to endotoxin, although the levels were
still somewhat below control. The improved PMφ func-
tion in 4.25-B/L over that in 1.5-D suggests that pH, and
not high glucose, is primarily responsible for altered PMφ
physiology.
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Fig. 3. Tumor necrosis factor a (TNFa ) secretion from macrophage
(PMφ) following exposure to lactate- and bicarbonate/lactate-buffered
peritoneal dialysis (PD) solutions. PMφ were incubated in PD so-
lutions for 15 or 30 minutes and then stimulated in medium with
lipopolysaccharide (10 lg/mL). Shown is the median supernatant lev-
els of TNFa after a 5-hour stimulation. HBSS, Hank’s Balanced Salt
Solution; 1.5-B/L, bicarbonate/lactate-buffered solution, 1.5% dex-
trose; 4.25-B/L, bicarbonate/lactate-buffered solution, 4.25% dextrose;
1.5-D, Dianeal, 1.5% dextrose. ∗Significantly lower than HBSS (P <
0.05); †Significantly lower than 1.5-B/L (P < 0.05). Adapted from
reference [109].
A study on PMN functional parameters conducted
by Topley et al [110] also suggested that neutral pH,
bicarbonate/lactate-buffered solutions show improved
biocompatibility over conventional solutions. PMNs iso-
lated from healthy donors were exposed to test solutions
for 30 minutes and the effect on cell viability, phago-
cytosis, and chemiluminescence analyzed. Test solutions
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included Dianeal, and 25 mmol/L bicarbonate/15 mmol/L
lactate-based solutions at pH 6.8 and 7.4, all contain-
ing 1.36% glucose. Only Dianeal caused a significant
decrease in cell viability, as evidenced by a decline in
cellular ATP content to 48% of control levels. The
bicarbonate/lactate solutions at pH 6.8 and 7.4 produced
results equivalent to the control medium, as did Dianeal
adjusted to pH 7.4 prior to assay. Similarly, LDH release,
another measure of cytotoxicity, was elevated above con-
trol levels only with Dianeal, pH 5.2.
Chemiluminescence was severely limited by the con-
ventional solution, while other tested solutions including
Dianeal pH 7.3 were not significantly different from con-
trol. Phagocytic capacity was decreased to 40% to 55%
of control by all tested solutions except Dianeal, which
decreased levels to <20% of control. Taken together,
these results illustrate a common finding that not all cell
functions are affected to the same degree by a partic-
ular solution (i.e., the bicarbonate/lactate solution had
no significant effects on cell viability and chemilumines-
cence, but caused a 50% decrease in phagocytic capac-
ity). Nonetheless, they do show that bicarbonate-based,
neutral pH solutions are more biocompatible and induce
a lower degree of cellular impairment than the conven-
tional solution and that impairment of leukocyte function
is mediated by pH.
Studies by Topley [110] and Rogachev [109] com-
pared the biocompatibility of pure bicarbonate- and
bicarbonate/lactate-buffered formulations in leukocyte
populations. While there were some minor differences
between these two buffer systems with regards to a spe-
cific cell function, there was no evidence to establish the
overall superiority of either buffer system.
The improved biocompatibility of bicarbonate/lactate-
buffered solutions on leukocyte function was confirmed
in another series of in vitro assays [111]. PBMCs from
healthy donors were incubated in two-fold diluted test
solutions for four hours, challenged with endotoxin, and
TNFa release assayed. Tested solutions included 1.5-D,
4.25-D, 1.5-B/L, 4.25-B/L, and 4.25% filter sterilized
Dianeal (4.25-DF), all neutralized prior to testing to elim-
inate the effect of pH. TNFa secretion decreased after
exposure to all solutions, with the greatest inhibition
seen with 4.25-D, suggesting an effect of glucose concen-
tration or hyperosmolality (Fig. 4A). However, because
there was no significant difference between 1.5-B/L and
4.25-B/L, it is more likely that the inhibitory effect in
this test system is due to the presence of GDPs in the
Dianeal solutions. This theory was strengthened by the
significant improvement in secretion with 4.25-B/L and
4.25-DF.
Superoxide production, phagocytic capacity, and
degranulation, three indicators of PMN function, were
found to be better preserved with the 25 mmol/L bicar-
bonate/15 mmol/L lactate solutions [111]. As shown in
Figure 4B, superoxide production was not significantly
changed from control levels with either 1.5-D or 1.5-B/L,
while the corresponding 4.25% solutions resulted in a sig-
nificant decrease. The finding that superoxide production
was least affected by 4.25-DF suggests that it is influenced
in part by factors other than glucose and osmolality, such
as GDPs.
Normal phagocytic function was also maintained to
a greater extent with bicarbonate/lactate solutions over
conventional solutions of the same glucose concentra-
tion and osmolality (Fig. 4C). Increasing the glucose con-
centration had an adverse effect on phagocytic activity,
regardless of the buffer system. 4.25-DF preserved
phagocytosis better compared to 4.25-D and 4.25-B/L,
again emphasizing the potential negative effect of GDPs
on cellular function.
These authors also examined PMN degranulation
capacity, as measured by endotoxin-stimulated BPI pro-
tein release. PMN exposed to bicarbonate/lactate solu-
tions showed better preserved degranulation capacity
compared to those exposed to Dianeal solutions of the
same glucose concentrations. At the higher glucose con-
centration of 4.25%, degranulation capacity was signifi-
cantly reduced only in Dianeal. There was no significant
difference in BPI release between 4.25-B/L and 4.25-DF,
and these levels approximated those found with 1.5-D
and 1.5-B/L. Sundaram concluded that the improved
biocompatibility of bicarbonate/lactate solutions may be
attributable, at least in part, to their lower GDP profile.
Levels of acetaldehyde and 5-HMF in the tested solu-
tions were highest in the heat-sterilized fluids and lowest
in the filter-sterilized and bicarbonate/lactate solutions
[111], supporting this hypothesis.
In summary, in vitro testing in leukocytes con-
firmed the improved biocompatibility of neutral pH,
bicarbonate/lactate-buffered PDF. The solution pre-
served pHi on acute exposure, improved cell viability,
and response to bacterial infection (e.g., phagocytosis,
superoxide radical generation, and endotoxin-stimulated
cytokine release). While not assayed in these studies, it
can be inferred that the increased apoptosis and necrosis
observed upon exposure to conventional fluids, thought
to be due to GDPs [53, 112], would be ameliorated with
the new solution. These observations suggest that Phys-
ioneal would preserve leukocyte function in vivo, result-
ing in a more normal response to, and decreased damage
from, infectious peritonitis.
BIOCOMPATIBILITY STUDIES WITH
PERITONEAL MESOTHELIAL CELLS
A number of studies have examined the biocompat-
ibility profile of neutral pH, bicarbonate/lactate-based
solutions, such as Physioneal, in mesothelial cells.
An early study by Topley et al [110] demonstrated
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that a neutral pH, bicarbonate/lactate solution better
preserved cell viability and cytokine production. Cell
viability, measured as intracellular ATP content, was
severely depressed after a 30 minute exposure of growth
arrested cells to 1.36% Dianeal. Exposure to a 25 mmol/L
bicarbonate/15 mmol/L lactate-based formulation at pH
7.4, and to Dianeal adjusted to pH 7.4 improved cell
viability, although it remained depressed relative to con-
trol. When the cells were transferred to M199 culture
medium post-exposure, ATP levels returned to normal
within a 60-minute recovery period, with no differences
between test and control cells. However, the ATP con-
tent of cells exposed to pH 5.2 Dianeal declined there-
after, implying a delayed effect of exposure to low pH
solution.
The effect on cell viability was also investigated by
Ha et al [113]. In a slightly different experimental for-
mat from that of Topley, growth-arrested synchronized
HPMC were exposed to undiluted solutions for up to
Fig. 4. Effects of bicarbonate/lactate- and lactate-based peritoneal
dialysis (PD) solutions on leukocyte functions. The effects of 1.5% Di-
aneal (1.5-D), 4.25% Dianeal (4.25-D), filter-sterilized 4.25% Dianeal
(4.25-DF), 1.5% bicarbonate/lactate solution (1.5-B/L), and 4.25% bi-
carbonate/lactate solution (4.25-B/L) were assayed in peripheral blood
mononuclear cells (PBMC) and polymorphonuclear cells (PMN) pop-
ulations. RPMI culture medium and Hank’s Balanced Salt Solution
(HBSS) served as a control media. (A) PBMC were exposed to test so-
lution for 4 hours, resuspended in RPMI containing 10 ng/mL endotoxin
for an additional 20 hours, and TNFa production assayed. (B) PMN
were exposed to test solution for 30 minutes, resuspended in HBSS,
and superoxide production assayed. (C) PMN were exposed to test so-
lution for 30 minutes, resuspended in HBSS, and uptake of heat-killed
14C-labeled Staphylococcus aureus over a 30 minute period measured.
Phagocytosis is expressed as a ratio of cell-associated counts/total counts
added. Adapted from reference [111].
96 hours, and cell death measured by LDH release.
Exposure of cells to 1.5-D, 4.25-D, and 4.25% Physioneal
40 (4.25-P) resulted in a 60% increase in LDH release
at 24 hours, with levels remaining elevated at 96 hours.
1.5-P had no significant effect. When the exposure time
to undiluted solutions was shortened to 60 minutes with
subsequent recovery in M199, LDH was increased only
in 1.5-D (4.25-D was not tested), with no effect seen with
1.5-P and 4.25-P. These results imply that cell viability is
influenced primarily by pH. However, when test solutions
were diluted two-fold in M199 prior to exposure (effec-
tively neutralizing solution pH), there was no increase
in LDH over control at 24 hours, while at 96 hours only
4.25-D increased LDH values (65% vs. 20% for control).
The finding that a two-fold dilution of 4.25-D, but not
4.25-P, significantly increased LDH release suggests that
high glucose may not be a major determinant of HPMC
cytotoxicity, and that another component of 4.25-D, such
as GDP content, is more influential.
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DNA damage, another marker of cell viability, was
measured after a 60-minute exposure to undiluted test
solutions. Exposure to both 1.5-D and 4.25-D, but not to
either 1.5-P or 4.25-P, resulted in measurable damage, the
extent of which could be attenuated by increasing the pH
of Dianeal to 7.4 prior to assay.
Ha et al [113] evaluated the effect of Physioneal on
a third parameter of HPMC function—proliferation.
Quiescent HPMC were incubated for up to 96 hours with
either control solution (M199) or test solutions diluted
two-fold with M199. Cell proliferation was unchanged in
cells exposed to 1.5-P, but was decreased in 1.5-D, 4.25-D,
and 4.25-P at 24 hours, and in 4.25-D and 4.25-P at
96 hours, suggesting an effect of glucose or hyperosmolal-
ity. When the cells were subjected to an acute 5-minute
exposure to undiluted solution followed by recovery in
M199, cell proliferation was significantly inhibited with
1.5-D and 4.25-P, but not by 1.5-P or, interestingly, 4.25-D.
The authors’ explanation for this apparently inconsis-
tent finding is that cell proliferation is adversely affected
by hyperosmolality, which accounts for the inhibition by
4.25-D and 4.25-P when cells are exposed over time to the
two-fold diluted solutions, and for the inhibition of 1.5-D
and 4.25-P upon acute exposure. However, after acute
exposure to undiluted 4.25-D, cellular mechanisms acti-
vated in response to high osmolality, low pH, and high
GDPs may have overcome the inhibitory effects of the
solution components, giving the impression that 4.25-D
does not negatively affect HPMC proliferation. This
would imply that these “response” mechanisms were not
activated in the presence 4.25-P.
A study recently published in abstract form com-
pared commercially available 25 mmol/L bicarbonate/
15 mmol/L lactate- and 40 mmol/L lactate-based so-
lutions with filter-sterilized 40 mmol/L lactate-buffered
solutions formulated with 1.36%, 2.27%, and 3.86%
glucose [abstract; Boulanger et al, Perit Dial Int 23(Suppl
1):S8, 2003]. HPMC proliferation was inhibited to a lesser
degree in bicarbonate/lactate versus lactate solutions at
all glucose concentrations tested. Even when the buffer
systems were equalized with the addition of lactate or
bicarbonate, the inhibitory effects were greater in the
lactate solutions, suggesting the importance of GDPs. In
addition, cell death and apoptosis were higher in 3.86%
lactate-buffered PDF than in the filtered and bicarbon-
ate/lactate solutions, implying that the high levels of
GDPs in the conventional lactate solutions reduce cell
viability independently of buffer and pH.
Solution biocompatibility in HPMC was also evaluated
in terms of cytokine production. IL-1–mediated IL-6 pro-
duction was significantly impaired relative to control after
exposure to undiluted 1.36-D, but not to a 1.36-B/L, pH
7.4 solution, or Dianeal that had been adjusted to pH 7.4
prior to exposure, suggesting pH as the causative agent
[110].
The effect of PD solutions on the secretion of growth
factors and extracellular matrix proteins in HPMC was
also evaluated. Cells were incubated for 48 hours in test
solutions diluted two-fold with M199 culture medium,
and the secretion of VEGF, TGF-b , procollagen I
C-terminal peptide (PICP), PIIINP, and fibronectin as-
sayed [114]. VEGF secretion was significantly enhanced
relative to control upon exposure to 1.5-D, 4.25-D, and
4.25-P, but not 1.5-P (Fig. 5A). For each solution tested,
VEGF secretion was higher upon exposure to 4.25% ver-
sus 1.5% solutions, suggesting a role for glucose. How-
ever, the extreme difference between 4.25-D and 4.25-P,
and the fact that VEGF levels with 1.5-D, 1.5-P, and 4.25-P
were all significantly lower than 4.25-D (22, 18, 28 vs.
65 ng VEGF/mg protein, respectively) suggests a
more substantial role of GDPs in VEGF produc-
tion. Supporting evidence comes from a study by
Mandl-Weber et al [93], who found that nonen-
zymatic glycation products upregulated VEGF pro-
duction in HPMC, while glucose had only a slight
inhibitory effect. HPMC production of PIIINP dis-
played the same pattern of secretion as VEGF, with in-
creased synthesis in all solutions, and levels in 4.25-D
and 4.25-P higher than 1.5-D and 1.5-P, respectively, and
4.25-P below 1.5-D (Fig. 5B). In addition, TGF-b produc-
tion was increased only in response to 4.25-D (Fig. 5C),
again implicating GDPs in regulation of protein secre-
tion. All solutions upregulated PIIIN to various degrees,
with both Dianeal solutions producing higher levels than
the Physioneal solutions, and the 4.25% solutions always
the most inhibitory of the two glucose concentrations. The
authors suggest that both high glucose and GDPs may
influence the production of VEGF, TGF-b , and PIIINP
to varying degrees.
The results from Ha illustrate how solution compo-
nents affect HPMC production of angiogenic factors and
ECM components, both of which contribute to peritoneal
fibrosis and alterations in membrane ultrafiltration, and
how these changes are greatly reduced in the presence
of Physioneal. That there was no significant increase in
secretion of either PICP or fibronectin (Fig. 5D) with
any of the solutions tested should be interpreted with
caution. These investigators have shown in an earlier
study that high glucose upregulates both TGF-b and fi-
bronectin through activation of protein kinase C [83],
and suggest that conditions in the present study may not
be conducive to fibronectin expression or that the solu-
tion may also contain negative regulators of fibronectin
[114].
In summary, the studies on mesothelial cells
indicate an improved biocompatibility of neutral
pH, bicarbonate/lactate-based PDF, as evidenced by
improved cell viability and proliferation, and response
to proinflammatory stimuli. The changes in expression
of various growth factors and ECM components imply a
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Fig. 5. Effects of peritoneal dialysis (PD) so-
lutions on the secretion of growth factor and
extracellular matrix (ECM) proteins by hu-
man peritoneal mesothelial cells (HPMC).
HPMC were cultured in various PD fluids
diluted two-fold with serum-free M199 for
48 hours, and the secretion of various
growth factors and ECM proteins mea-
sured by enzyme-linked immunosorbent
assay (ELISA) [vascular endothelial growth
factor (VEGF), transforming growth factor-b
(TGF-b), and fibronectin) or radioimmunoas-
say (RIA) [procollagen III peptide (PIIINP)].
Test solutions used were: 1.5% Dianeal
(1.5-D), 4.25% Dianeal (4.25-D), 1.5% Phys-
ioneal (1.5-P), and 4.25% Physioneal (4.25-P).
Results are given as ng protein/mg total cel-
lular protein. ∗P < 0.05 compared with M199;
†P < 0.05 compared to 1.5-D). Adapted from
reference [114].
reduced potential for changes in angiogenesis, peritoneal
transport, and peritoneal fibrosis, all suggesting the possi-
bility for better preservation of membrane structure and
function.
PERITONEAL FIBROBLASTS
The improved biocompatibility of a bicarbon-
ate/lactate solution was demonstrated in L-929 fibroblasts
upon exposure to two-fold dilutions of 3.86-D, filter-
sterilized 3.86%D (3.86-DF), and a 25 mmol/L bicar-
bonate/15 mmol/L lactate solution also containing 3.86%
glucose. The proliferative capacity of cells exposed to
the bicarbonate/lactate solution showed a minor, non-
significant decrease relative to control and the filter-
sterilized Dianeal, while exposure to 3.86-D resulted in
a greater than 60% inhibition of cell growth [115]. This
inhibition was attributed to the presence of GDPs, as
both the bicarbonate/lactate and the filtered solutions
showed decreased or undetectable levels of acetalde-
hyde. These results support an earlier study in primary
peritoneal fibroblasts that suggested that bicarbonate-
buffered solutions were less cytotoxic than conventional
solutions as measured by preservation of IL-1 mediated
IL-6 release, and that peritoneal fibroblasts appeared to
be more resistant to PD solution–mediated cytotoxicity
than primary mesothelial cells [108].
OVERVIEW OF IN VITRO
BIOCOMPATIBILITY TESTING
In vitro cell culture studies, the first level of preclini-
cal biocompatibility testing, provide a platform for eval-
uating the effect of specific solution components on cell
viability and function. These studies show quite clearly
that in leukocyte, mesothelial, and fibroblast cell pop-
ulations Physioneal is more biocompatible and better
preserves cellular function in vitro than conventional
acidic lactate-based PDF. The improved biocompatibil-
ity appears largely attributable to the change to neutral
pH, bicarbonate/lactate buffer and the reduction in GDP
levels (see Table 4).
It is notable that none of the reviewed studies identified
glucose as a primary causative agent of bioincompatibil-
ity, despite numerous in vitro studies that have shown
definite adverse effects when added directly to cultured
cells. While high glucose (4.25%) lactate PDF proved
more detrimental to cell viability and cell function than
the 1.5% lactate solutions, 4.25% bicarbonate/lactate
solution preserved normal cellular physiology to a greater
degree, often having an effect similar to 1.5% lactate, or
even control media. In comparisons of filter- and heat-
sterilized solutions, the biocompatibility of high glucose
filter-sterilized media was decidedly superior, and of-
ten comparable to that of low glucose or control media.
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These two observations suggest that a factor in PDF other
than, or in addition to, glucose has a strong influence on
biocompatibility, and the other factor is most likely the
presence of GDPs. This should not be interpreted to
downplay the contributions of glucose to bioincompat-
ibility or to negate the numerous studies showing a
glucotoxic effect, but suggests that under the conditions
assayed in the reviewed studies, GDPs may have a higher
degree of cytotoxicity.
The majority of the studies reviewed here suggest
GDPs are causative agents of bioincompatibility, as they
are implicated in impaired leukocyte, mesothelial cell,
and fibroblast function (Table 3). This is an interest-
ing observation, especially in light of cell culture studies
using pure forms of individual GDPs. These studies show
variable outcomes, ranging from effects only after long-
term [54] versus short-term [56] exposure, from no effects
to effects only with selected GDPs [48, 56].
Physioneal has achieved increased biocompatibility
over conventional solutions through a change to a
bicarbonate/lactate-based, neutral pH solution, with a
significantly lower GDP content despite its continued use
of glucose as the osmotic agent. In light of the changed for-
mulation, how significant will glucose-mediated effects be
on membrane function and longevity? It is possible that as
overall solution biocompatibility improves, as appears to
be the case with Physioneal, normal membrane structural
and functional characteristics will be better maintained
over the course of the therapy, resulting in preservation
of ultrafiltration capacity and transport status. Improved
membrane viability may reduce or moderate the overall
cytotoxic effects of glucose in two ways. First, preserved
dialysis capacity may reduce the need to use high glucose
solutions to achieve adequate ultrafiltration, and result
over time in lower solution glucose exposure. Second, a
healthier membrane may be more resistant to, and better
able to recover from, glucose-mediated damage.
An important message derived from these studies is
that solution components can affect cellular functions in
different ways. The observations that cell viability is af-
fected mainly by GDPs and low pH, DNA damage is
related to pH, cell proliferation is affected by hyperosmo-
lality, and protein expression in leukocytes and mesothe-
lial cells is strongly regulated by GDPs, indicate that
biocompatibility is multifactorial. In addition, specific cell
types have different sensitivities to, and are affected in
different ways, by PD solutions. Therefore, when extrap-
olating observations on in vitro biocompatibility to what
might be expected in vivo, it is essential to take into
account the effects on all cell populations. The physiology
of the peritoneal membrane is determined by the interac-
tions of resident and transient cell populations. Therefore,
when evaluating biocompatibility, one must look not only
at the direct effects of exposure on all relevant cell pop-
ulations, but at secondary effects as well—how the initial
exposure can set in motion signaling cascades from one
cell population to another. As such, it will be the collec-
tive and blended responses of all affected cell types that
ultimately determine overall membrane health.
ADEQUACY OF STUDIES IN DEFINING
BIOCOMPATIBILITY
The biocompatibility studies reviewed here provide
information on solution cytotoxicity and insight into
the effects on inflammatory response, angiogenesis and
capillary permeability, fibrosis, and ECM deposition,
cellular and molecular changes relevant to membrane
performance in vivo. These studies provide a fairly com-
prehensive evaluation of solution biocompatibility in
leukocyte and mesothelial cell populations; in contrast,
there was a single study in L-929 fibroblasts and no stud-
ies to date using cells of the peritoneal vasculature. As
these cells are significant contributors to both normal
membrane physiology, as well as processes of fibrosis,
neoangiogenesis, and vasculopathy, hallmarks of mem-
brane deterioration and ultrafiltration failure, inclusion
of these cell types in future biocompatibility studies is
strongly recommended.
Also recommended are studies based on the use of
cell culture supernatants or preconditioned media. These
studies would be of considerable value in assessing
solution biocompatibility in endothelial and fibroblast
populations. As residents of the interstitial space,
endothelial cells, vascular smooth muscle cells, and fi-
broblasts are not directly exposed to solutions in vivo,
although they are exposed to glucose and GDPs trans-
ported from the peritoneal lumen. These cells do
respond to molecular signals from peritoneal leukocytes
and mesothelial cells, however, and therefore would be
affected in large part through these signaling pathways.
Therefore, culture of these cells with supernatants from
leukocytes and mesothelial cells exposed to PDF would
be a valid means to assess solution biocompatibility.
These studies would also provide needed information on
the cell-cell interactions and offer sights into the indirect
(but no less significant) effects of PD solutions.
CONTRIBUTIONS TO THE NEXT
LEVELS OF STUDIES
In vitro biocompatibility studies should provide a ba-
sis for moving forward with the next level(s) of testing.
Improvements in cellular functional parameters demon-
strated in cell culture studies (Table 3) can now be
investigated in animal models of acute and chronic ex-
posure to PDF. A major objective of the animal studies is
to determine whether the conclusions drawn from the in
vitro biocompatibility studies can be confirmed in vivo.
One of the limitations of in vitro studies is the difficulty in
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evaluating processes that occur over long periods of time,
such as AGE formation and its subsequent effects. The
reduced levels of GDPs in Physioneal, and the decreased
rate and level of AGE formation in vitro [72], imply a re-
duction in AGE formation in vivo. Confirmation of this
and subsequent changes in membrane functional param-
eters must now come from animal studies and clinical
biopsies.
ARE IN VITRO STUDIES PREDICTIVE OF IN
VIVO BIOCOMPATIBILITY?
One of the main questions regarding in vitro studies
is whether they are predictive of, or accurately reflect
in vivo biocompatibility. One would like to assume that
biocompatibility could be predicted with some degree of
accuracy on the basis of preclinical biocompatibility test-
ing. In fact, preliminary results in PD patients indicate
that Physioneal is more biocompatible based on effluent
markers indicating improved membrane health and pre-
served mesothelial cell function [116, 117]. A definitive
answer will come from prospective clinical studies on pa-
tients using Physioneal for a long enough period so that
any solution effects are reflected not only in structural
characteristics of the membrane (e.g., AGE deposition,
vasculopathy) but functional parameters as well.
When evaluating solution biocompatibility, it must be
remembered that solution components are not the only
factors influencing membrane function and longevity as
a dialyzing organ. Membrane structure and function in
renal disease patients are also affected by the uremic envi-
ronment. It has been proposed that the peritoneal cavity
of PD patients is in a state of severe overload of carbonyl
stress compounds derived not only from glucose-based
dialysis solutions, but from the uremic circulation as well
[106, 118]. Components of the submesothelial space and
the interstitium—ECM components, fibroblasts, resident
macrophages, and cells of the peritoneal vasculature—
are exposed not only to glucose and GDPs moving from
the peritoneal cavity into the submesothelial space and
interstitium, but to RCOs and glucose moving from the
uremic circulation into the peritoneal lumen. This bidi-
rectional transport places these cellular components at
increased risk for AGE modification. AGEs and ALEs
have been localized to the peritoneal membrane of nor-
moglycemic uremic patients prior to the initiation of PD,
an observation that emphasizes the contributions of the
uremic circulation and oxidative stress, per se, to AGE
formation and membrane damage [105], and indicates
that this process is at least partially independent of PD.
The health of the membrane and its longevity as a
dialyzing tissue is influenced both by the uremic envi-
ronment and chronic exposure to PDF. This necessitates
a dual approach to improving PD as a viable, long-term
renal replacement therapy. We must not only continue
to investigate innovative strategies to improve the bio-
compatibility of dialysis solutions, but at the same time
treat the underlying kidney disease and uremic condi-
tion, as well as comorbid conditions such as diabetes and
hypertension.
CONCLUSION
In vitro biocompatibility testing has clearly demon-
strated that neutral pH, bicarbonate/lactate-buffered
Physioneal solutions are superior to conventional solu-
tions in preserving cell viability and function. They have
proven valuable in confirming the basic safety of the
solution, identified predictive markers of cell function,
and provided a basis for moving forward with the next
stages in preclinical testing. The goal for all in vitro bio-
compatibility studies should be the use of an experimental
design that involves all relevant cell populations, mim-
ics cell-to-cell interactions and molecular signaling path-
ways, and recreates the in vivo environment as closely as
possible, so that in vivo solution biocompatibility can be
predicted with the highest degree of confidence. While
these studies cannot take the place of long-term clinical
studies, and cannot fully address the comorbid conditions
that influence technique survival, they do play an integral
role in PD solution development.
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